Melanoma Vaccine Ushers in New Hope for Cancer Patients — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna announced that their experimental personalized vaccine reduced melanoma recurrence risk by 42% over two years compared to patients who did not receive it.
- The companies have not yet demonstrated that the vaccine prolongs overall survival for melanoma patients.
- Researchers are now testing similar therapeutic vaccine approaches for other cancers, including glioblastoma and pancreatic cancer.
- The National Cancer Institute's Dr. Steven Rosenberg noted that thousands of papers have been written on therapeutic cancer vaccines, a field with decades of prior attempts.
- Recent investments include a $200 million federal public-private partnership and a dedicated vaccine center established in 2024 at Memorial Sloan Kettering Cancer Center.
- Scientists express caution, noting it's unclear if other cancers will respond as favorably as melanoma, which is particularly receptive to immune-based therapies.
Why it matters: For cancer patients, especially those with melanoma, this represents a potential new treatment modality that directly targets their specific tumors. The significant financial and institutional backing signals a major shift from research to development, aiming to overcome historical failures in the field.
Ask SkimNews
